DEERFIELD, Ill. & RIDGEFIELD, Conn.--(BUSINESS WIRE)--Walgreens and Boehringer Ingelheim today announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable. This collaboration will offer people an opportunity to learn about and potentially participate in an important Phase III clinical trial within the familiar and accessible environment of Walgreens pharmacies, reflecting a shared vision to expand access to healthcare and research..

伊利诺伊州迪尔菲尔德和康涅狄格州里奇菲尔德——（商业新闻短讯）——沃尔格林和勃林格殷格翰今天宣布了一项战略合作，旨在优化招聘，使临床试验更容易获得，更具包容性和公平性。这项合作将为人们提供一个机会，在沃尔格林药店熟悉且易于获得的环境中了解并可能参与一项重要的III期临床试验，反映出扩大医疗保健和研究的共同愿景。。

Through this collaboration, Boehringer Ingelheim will leverage select Walgreens community pharmacies as clinical trial sites for people living with obesity, overweight and type 2 diabetes. The effort aims to dismantle barriers, improve access, and address equitable health representation in clinical trials, especially among Black and Hispanic adults who are more likely to have obesity in the U.S.

通过这次合作，勃林格殷格翰将利用选定的沃尔格林社区药店作为肥胖、超重和2型糖尿病患者的临床试验场所。这项努力旨在消除障碍，改善获得机会，并在临床试验中解决公平的健康代表性问题，特别是在美国更有可能肥胖的黑人和西班牙裔成年人中。

and have historically been underrepresented..

而且历史上代表性不足。。

“Embracing our pharmacy clinical trial centers in this study underscores our joint commitment to community health and innovation,” said Ramita Tandon, Chief Clinical Trials Officer at Walgreens. “This model not only provides foundational education on clinical research for patients but also empowers individuals, offering them a new pathway to engage in their healthcare through clinical trial participation.

Walgreens首席临床试验官拉米塔·坦登（RamitaTandon）表示：“在这项研究中拥抱我们的药学临床试验中心，突显了我们对社区健康和创新的共同承诺。”。“这种模式不仅为患者提供了临床研究的基础教育，而且赋予了个人权力，为他们提供了一条通过临床试验参与医疗保健的新途径。

It’s a step forward in transforming the landscape of clinical research, helping to make clinical trials more inclusive and accessible.”.

这是改变临床研究格局的一个进步，有助于使临床试验更具包容性和可及性。”。

Additionally, Boehringer is partnering with EmVenio Research to complement this initiative by introducing mobile research units to extend reach and provide additional options for participation.

此外，勃林格正在与EmVenio Research合作，通过引入移动研究单位来扩大覆盖范围并提供更多参与选择，以补充这一举措。

“Boehringer is proud to embrace this community-centric approach to clinical research with Walgreens and EmVenio,” said Lennart Jungersten, Senior Vice President, Medicine & Regulatory Affairs at Boehringer Ingelheim U.S. “By bringing clinical trials into the heart of local communities, we’re making them more accessible, helping to provide access to diverse populations with pressing health needs to participate in our clinical trials.

“勃林格殷格翰美国医学与监管事务高级副总裁伦纳德·荣格斯滕（LennartJungersten）表示：“勃林格殷格翰很自豪能与沃尔格林和埃姆维尼奥（Walgreens and EmVenio）一起采用这种以社区为中心的临床研究方法。通过将临床试验纳入当地社区的核心，我们正在使其更容易获得，有助于让有迫切健康需求的不同人群参与我们的临床试验。

Boehringer Ingelheim is committed to helping those living with overweight and obesity to transform lives for generations to come.”.

勃林格殷格翰致力于帮助那些超重和肥胖的人改变后代的生活。”。

It is estimated that over 1 billion people in the world live with obesity, and numbers are continuing to rise, with an estimated 24% of the entire world population affected by 2035. Obesity is included among cardiovascular, renal and metabolic (C-R-M) diseases, and, collectively, these are the leading cause of death worldwide..

据估计，世界上有超过10亿人患有肥胖症，而且这个数字还在继续上升，到2035年，估计全世界有24%的人口受到影响。肥胖包括在心血管，肾脏和代谢（C-R-M）疾病中，总的来说，这些是全球死亡的主要原因。。

“At EmVenio, we believe that innovation is meaningful and access to clinical trial research should be universal. Our partnership with Boehringer Ingelheim exemplifies our commitment to breaking down barriers and expanding access to transformative healthcare solutions,” says Thad Wolfram, President, EmVenio Research.

EmVenio research总裁Thad Wolfram表示：“在EmVenio，我们认为创新是有意义的，临床试验研究应该是普遍的。我们与勃林格殷格翰的合作证明了我们致力于打破障碍，扩大获得变革性医疗解决方案的机会。”。

“By bringing clinical trials directly to local communities, we're not just conducting research, we're fostering inclusivity and diversity in clinical trials.”.

“通过将临床试验直接带到当地社区，我们不仅在进行研究，还在促进临床试验的包容性和多样性。”。

Leveraging pharmacies and mobile research units for clinical trial research is a forward-thinking approach with the potential to enhance patient outcomes and set a new benchmark for inclusivity. Walgreens will also utilize advanced, real-world insights to identify and engage potential study participants as part of the collaboration..

利用药房和流动研究单位进行临床试验研究是一种前瞻性的方法，有可能提高患者的预后，并为包容性设定新的基准。作为合作的一部分，沃尔格林还将利用先进的现实世界见解来识别和吸引潜在的研究参与者。。

About Boehringer in Cardiovascular, Renal and Metabolic (C-R-M) Diseases

关于勃林格在心血管、肾脏和代谢（C-R-M）疾病中的作用

Boehringer Ingelheim is committed to improving the lives of people living with interconnected cardiovascular, renal and metabolic (C-R-M) diseases. Our ambition is to create innovative, people-centric solutions for those living with one or more C-R-M diseases, to protect them from the consequences of these conditions..

勃林格殷格翰致力于改善心血管、肾脏和代谢（C-R-M）疾病患者的生活。我们的目标是为患有一种或多种C-R-M疾病的患者创造创新的、以人为中心的解决方案，以保护他们免受这些疾病的影响。。

Affecting over 1 billion lives globally, C-R-M diseases – including overweight and obesity – are the leading cause of death worldwide, accounting for up to 20 million deaths annually. C-R-M diseases are interconnected, coexist and can amplify one another, resulting in a significant burden on patients' lives.

C-R-M疾病（包括超重和肥胖）影响全球超过10亿人的生命，是全球死亡的主要原因，每年造成多达2000万人死亡。C-R-M疾病是相互关联的，共存的，并且可以相互放大，从而对患者的生活造成重大负担。

It is estimated that over 1 billion people in the world live with obesity, and numbers are continuing to rise, with an estimated 24% of the entire world population affected by 2035..

据估计，世界上有超过10亿人患有肥胖症，而且这个数字还在继续上升，到2035年，估计全世界有24%的人口受到影响。。

About Walgreens

关于沃尔格林

Walgreens (www.walgreens.com) is included in the U.S. Retail Pharmacy and U.S. Healthcare segments of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail leader. True to its purpose of “more joyful lives through better health,” Walgreens has a more than 120-year heritage of caring for communities and providing trusted pharmacy services, and today is playing a greater role as an independent partner of choice offering healthcare services that improve care, lower costs, and help patients.

Walgreens（www.Walgreens.com）是Walgreens Boots Alliance，Inc.（纳斯达克：WBA）的美国零售药房和美国医疗保健分部，Walgreens Boots Alliance是一家综合医疗保健、药房和零售领导者。沃尔格林秉承“通过更好的健康让生活更快乐”的宗旨，在关心社区和提供值得信赖的药房服务方面拥有120多年的传统，如今，沃尔格林作为一个独立的首选合作伙伴，正在发挥更大的作用，提供改善护理、降低成本和帮助患者的医疗服务。

Operating nearly 9,000 retail locations across the U.S. and Puerto Rico, Walgreens is proud to serve nearly 9 million customers and patients daily. The company’s pharmacists are playing a more critical role in healthcare than ever before, providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for some of the nation’s most underserved populations.

沃尔格林在美国和波多黎各经营着近9000家零售店，每天为近900万客户和患者提供服务。该公司的药剂师在医疗保健领域发挥着前所未有的关键作用，提供了广泛的药房和医疗保健服务，包括那些为美国一些服务最不足的人群提供公平医疗服务的服务。

Walgreens offers customers and patients a true omnichannel experience, with fully integrated physical and digital platforms designed to deliver high-quality products and healthcare services. Within the U.S. Healthcare segment, Walgreens portfolio also includes businesses in primary care, multi-specialty, post-acute care, urgent care, specialty pharmacy services, population health and provider enablement..

沃尔格林通过完全集成的物理和数字平台为客户和患者提供真正的全渠道体验，旨在提供高质量的产品和医疗保健服务。在美国医疗保健领域，沃尔格林的投资组合还包括初级保健、多专业、急性后护理、紧急护理、专业药房服务、人口健康和提供者支持等业务。。

About Boehringer Ingelheim

关于勃林格殷格翰

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain.

勃林格殷格翰是一家活跃于人类和动物健康领域的生物制药公司。作为该行业研究和开发的最大投资者之一，该公司专注于在高度未满足医疗需求的领域开发创新疗法。自1885年成立以来，勃林格一直保持着长期的独立性，将可持续性贯穿于整个价值链。

More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Discover more at www.boehringer-ingelheim.com/us..

超过53500名员工服务于130多个市场，以建立一个更健康、更可持续和公平的明天。更多信息，请访问www.boehringer-ingelheim.com/us。。

About EmVenio Research

关于EmVenio Research

EmVenio Research provides rapid and scalable mobile community research site solutions to better reach and recruit diverse, underrepresented and high-risk communities. EmVenio Research’s global network of skilled clinicians, principal investigators and state-of-the-art mobile community research sites enable us to provide robust clinical research services via home visits, on-site support at medical facilities, virtual visits and mobile sites.

EmVenio Research提供快速且可扩展的移动社区研究网站解决方案，以更好地接触和招募多样化、代表性不足和高风险的社区。EmVenio Research由熟练的临床医生、主要研究人员和最先进的移动社区研究网站组成的全球网络使我们能够通过家访、医疗设施的现场支持、虚拟访问和移动网站提供强大的临床研究服务。

Visit emvenio.com to learn more..

访问emvenio.com了解更多。。